Ad is loading...
AEIUX
Price
$9.54
Change
+$0.08 (+0.85%)
Updated
Nov 21 closing price
VVIAX
Price
$69.72
Change
+$0.84 (+1.22%)
Updated
Nov 21 closing price
Ad is loading...

AEIUX vs VVIAX

Header iconAEIUX vs VVIAX Comparison
Open Charts AEIUX vs VVIAXBanner chart's image
American Century Equity Income R5
Price$9.54
Change+$0.08 (+0.85%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index Adm
Price$69.72
Change+$0.84 (+1.22%)
VolumeN/A
CapitalizationN/A
AEIUX vs VVIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
AEIUX vs. VVIAX commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AEIUX is a Sell and VVIAX is a Buy.

FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 184B vs. AEIUX (7.62B). AEIUX pays higher dividends than VVIAX: AEIUX (2.50) vs VVIAX (2.36). AEIUX was incepted earlier than VVIAX: AEIUX (8 years) vs VVIAX (24 years). AEIUX is a more actively managed with annual turnover of: 29.00 vs. VVIAX (10.00). AEIUX has a lower initial minimum investment than VVIAX: AEIUX (0) vs VVIAX (3000). VVIAX annual gain was more profitable for investors over the last year : 26.09 vs. AEIUX (13.81). VVIAX return over 5 years is better than : 53.09 vs. AEIUX (14.90).
AEIUXVVIAXAEIUX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years24 years-
Gain YTD15.55319.67279%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets7.62B184B4%
Annual Yield % from dividends2.502.36106%
Returns for 1 year13.8126.0953%
Returns for 3 years1.3824.776%
Returns for 5 years14.9053.0928%
Returns for 10 yearsN/A112.26-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOLE15.260.19
+1.26%
Dole plc
NCNO40.450.37
+0.92%
nCino
SGHT3.760.03
+0.80%
Sight Sciences
VICI32.370.25
+0.78%
VICI Properties
SABS3.070.01
+0.33%
SAB Biotherapeutics